Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Swartz MS, Perkins DO, Stroup TS, et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE Study. Am J Psychiatry 2007;164:428–36.
Randomised controlled trial.
Eighteen months (treatment period only).
Fifty seven clinical sites in the USA; January 2001 to December 2004.
1493 adults with DSM-IV schizophrenia were randomised in the Clinical Antipsychotic Trial of Intervention Effectiveness (CATIE) study. This publication reports on the 455 participants who were assessed for the primary outcome measure at baseline and 12 months. Main exclusions: history of antipsychotic resistance, only one previous schizophrenic episode, schizoaffective disorder, mental retardation, other cognitive disorders, pregnant or breast feeding, or serious medical comorbidity.
Olanzapine (7.5–30 mg), quetiapine (200–800 mg), risperidone (1.5–6 mg), …
Sources of funding: National Institute of Mental Health, USA; The Foundation of Hope, Raleigh, NC. Study medications were provided by AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eli Lilly and Company, Forest Pharmaceuticals Inc, Janssen Pharmaceutica Products LP, Otsuka Pharmaceuticals Co Ltd, Pfizer Inc, and Zenith Goldline Pharmaceuticals Inc.
Competing interests: None declared.